Given its high sensitivity and negative predictive value, French researchers are promoting FDG-PET/CT for its ability to assess response to treatment and redirect therapy for patients with recurrent or progressive anal cancer, in a study published in the September issue of the Journal of Nuclear Medicine. {read more here}